Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)

NCT02255422 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02255422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02255422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
May 5, 2015
Completion date
November 30, 2017
Enrollment
53 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

mitochondrial myopathies